| Cash flow (USD) | Q2 2025 ended Jun 30, 2025 | Q2 2025 ended Mar 31, 2025 | Q2 2024 ended Jun 30, 2024 | Q2 2024 ended Mar 31, 2024 | Q2 2023 ended Jun 30, 2023 | Q1 2023 ended Mar 31, 2023 | Q4 2022 ended Dec 31, 2022 | Q3 2022 ended Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|
| Net income | -2.06M | -3.32M | -3.63M | -3.87M | -7.97M | -8.75M | -8.27M | -8.08M |
| Depreciation and amortization | 16.0K | 16.0K | 14.0K | 17.0K | ||||
| Stock-based compensation | 639.0K | 484.0K | 740.0K | 836.0K | ||||
| Cash from operations | -7.49M | -7.19M | -5.70M | -5.25M | ||||
| Capital expenditure | -2.0K | -1.0K | -1.0K | -42.0K | ||||
| Free cash flow | -7.49M | -7.19M | -5.70M | -5.30M | ||||
| Cash from investing | -4.27M | 14.43M | 9.35M | 6.07M | ||||
| Cash from financing | 1.37M | 0 | -869.0K | 39.0K | ||||
| Net change in cash | -10.39M | 7.25M | 2.78M | 858.0K |
From Chemomab Therapeutics Ltd.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.